全文获取类型
收费全文 | 222篇 |
免费 | 12篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 3篇 |
基础医学 | 17篇 |
口腔科学 | 10篇 |
临床医学 | 19篇 |
内科学 | 49篇 |
皮肤病学 | 3篇 |
神经病学 | 15篇 |
特种医学 | 2篇 |
外科学 | 17篇 |
综合类 | 3篇 |
预防医学 | 36篇 |
眼科学 | 1篇 |
药学 | 16篇 |
肿瘤学 | 38篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 43篇 |
2020年 | 21篇 |
2019年 | 27篇 |
2018年 | 18篇 |
2017年 | 12篇 |
2016年 | 9篇 |
2015年 | 3篇 |
2014年 | 5篇 |
2013年 | 6篇 |
2012年 | 12篇 |
2011年 | 18篇 |
2010年 | 9篇 |
2009年 | 3篇 |
2008年 | 4篇 |
2007年 | 5篇 |
2006年 | 8篇 |
2005年 | 4篇 |
2003年 | 7篇 |
2002年 | 2篇 |
2001年 | 3篇 |
1999年 | 2篇 |
1996年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有234条查询结果,搜索用时 174 毫秒
1.
Rene E Sotomayor Melissa Washington Linh Nguyen Rahma Nyang'anyi Dennis M Hinton Ming Chou 《Toxicological sciences》2003,73(2):329-338
We studied the effects of intermittent exposure to aflatoxin B1 (AFB1) on hepatic DNA and RNA adduct formation. Fisher-344 male rats were fed 0.01, 0.04, 0.4, or 1.6 ppm of AFB1 intermittently for 8, 12, 16, and 20 weeks, alternating with 4 weeks of dosing and 4 weeks of rest. Other groups of rats were fed 1.6 ppm of AFB1 continuously for 4, 8, 12, and 16 weeks. Control rats received AFB1-free NIH-31 meal diet. AFB1-DNA and -RNA adducts were measured by HPLC with fluorescence detection. The data are presented as total DNA or RNA adducts. The DNA and RNA adduct levels increased or decreased depending on the cycles of dosing and rest. Rats removed from treatment 1 month after 1 or 2 dosing cycles (8 and 16 weeks of intermittent exposure) showed approximately a twofold decrease in DNA adduct levels and a two- to elevenfold decrease in RNA adduct levels compared with rats euthanized immediately after the last dosing cycle (12 and 20 weeks of intermittent exposure). Our data indicate that DNA and RNA adducts increased linearly, from 0.01 ppm to 1.6 ppm of AFB1 after 12 and 20 weeks of intermittent treatment. A linear dose response was also apparent for DNA but not for RNA adducts after 8 and 16 weeks of treatment. As biomarkers of exposure, AFB1-RNA adducts were three to nine times more sensitive than AFB1-DNA adducts but showed greater variability. These results suggest that binding of AFB1 to hepatic DNA is a linear function of the dose, regardless of the way this is administered. The dose-response relationship for RNA adducts depends on the length of the no-dosing cycles and on the turnover rate of RNA. 相似文献
2.
Rahma Warsame Soo Mee Bang Shaji K. Kumar Morie A. Gertz Martha Q. Lacy Francis Buadi David Dingli Suzanne R. Hayman Prashant Kapoor Robert A. Kyle Nelson Leung John A. Lust Stephen J. Russell Thomas E. Witzig Steven R. Zeldenrust S. Vincent Rajkumar Angela Dispenzieri 《European journal of haematology》2014,92(6):485-490
Immunoglobulin light chain (AL) Amyloidosis is a condition whereby misfolded proteins generated by plasma cells deposit in tissues causing organ dysfunction. Chemotherapy and autologous stem cell transplant when eligible are standard treatment options. Several studies report long‐term outcomes of patients post‐transplant. However, there is a paucity of literature describing outcomes of relapsed patients post‐transplant. We performed a retrospective study to assess outcomes and therapies employed upon relapse after transplant. Between 1996 and 2009, 410 patients received transplant at the Mayo Clinic as first‐line therapy. Of those patients, 42 (10%) died within 3 months of transplant, 64 (16%) died without documented relapse, 158 (38%) were alive without documented progression, and 146 (36%) had documented progression. Those 146 patients are the subject of our study, and their median time to hematologic relapse/progression was 23.6 months (95%CI 18.3, 26.3 months). Their median overall survival and 5‐yrs overall survival from post‐transplant relapse/progression was 51.7 months (95%CI 34.1–62.3) and 39%, respectively. The most common first regimen for treatment after relapse was lenalidomide or thalidomide. In conclusion, our study indicates that patients with AL amyloidosis fare well post‐transplant relapse/progression. Additionally, it provides a yardstick to design clinical trials to determine best treatment options. 相似文献
3.
4.
Chaima Rachdi Rahma Damak Feten Fekih Romdhane Haroun Ouertani Majda Cheour 《Primary Care Diabetes》2019,13(1):57-62
Aim
Depression is prevalent in patients with type 2 diabetes. It may have a negative impact on the management of diabetes mellitus and could affect weight. The main aim of the investigation was to evaluate the effect of antidepressant treatment (sertraline) on anthropometric variables and glycemic control in depressed type 2 diabetic patients.Methods
Thirty three type 2 diabetic outpatients depressed received open-label sertraline therapy for up to 12 weeks. Clinical outcome measures included the 17-item Hamilton depression rating. Changes in the anthropometrics variables were evaluated by measuring weight, waist circumference and by calculating body mass index at three, six and 12 weeks of treatment. In addition, fasting, postprandial plasma glucose level, glycosylated hemoglobin-A 1C measures, lipid and renal profile were obtained before and during sertraline therapy.Results
Weight decreased significantly (?2 kg; p = 0.000) and body mass index decreased from 30.41 kg/m2 to 29.6 kg/m2 (p = 0.000). Patients lost on average seven centimeters in waist circumference (p = 0.000). We also observed a modest, non-significant reduction in fasting, postprandial and glycosylated hemoglobin. We observed a significant reduction in mean score according to the Hamilton depression scale (p = 0.000)Conclusion
Our study results suggested that sertraline produced a benefic effect on weight, body mass index and waist circumference at 12-week follow up. 相似文献5.
Rheumatoid arthritis (RA) mainly affects various joints of the body, including the temporomandibular joint (TMJ), and it involves an infiltration of autoantibodies and inflammatory leukocytes into articular tissues and the synovium. Initially, the synovial lining tissue becomes engaged with several kinds of infiltrating cells, including osteoclasts, macrophages, lymphocytes, and plasma cells. Eventually, bone degradation occurs. In order to elucidate the best therapy for RA, a comprehensive study of RA pathogenesis needs to be completed. In this article, we discuss a Fas-deficient condition which develops into RA, with an emphasis on the role of sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling which induces the migration of osteoclast precursor cells. We describe that Fas/S1P1 signaling via NF-κB activation in osteoclasts is a key factor in TMJ-RA severity and we discuss a strategy for blocking nuclear translocation of the p50 NF-κB subunit as a potential therapy for attenuating osteoclastogenesis. 相似文献
6.
7.
3-Aminopropyltriethoxysilane (APTES) is a silane widely used to supply amino groups for further modifications on various materials, but it is less studied as a catalyst to catalyze sol–gel silica polymerization. Here, by using APTES as the catalyst instead of the conventional basic catalysts, a novel strategy was developed to prepare silica-based molecularly imprinted polymers (MIPs). Meanwhile, APTES was employed as the functional monomer to create imprinted nanocavities for specific recognition of target molecules. The as-synthesized MIP exhibited ultra-high recognition capability due to the elimination of the detrimental effect on the imprinting performance caused by the additional catalysts. The preparation process, specificity, pH effect, binding capacity and affinity of the MIP were studied in detail. The MIP microparticles could be packed into a solid phase extraction column for removing the target molecule in water efficiently, and the molecule could easily be enriched by 40 times. The interaction of the functional monomer and template was studied by the calculation method, giving a more clear understanding of the recognition behaviours of the imprinted polymers. The strategy could be extended not only to prepare highly specific MIPs for other small phosphoric molecules, but also for biomolecules e.g. phosphorylated peptides or proteins.A novel strategy was developed for preparing highly selective molecularly imprinted polymers using 3-aminopropyltriethoxysilane as both a functional monomer and catalyst. 相似文献
8.
9.
10.
Eli Muchtar Morie A. Gertz Martha Q. Lacy Nelson Leung Francis K. Buadi David Dingli Suzanne R. Hayman Ronald S. Go Prashant Kapoor Wilson Gonsalves Taxiarchis V. Kourelis Rahma Warsame Yi Lisa Hwa Amie Fonder Miriam Hobbs Stephen Russell John A. Lust Mustaqeem Siddiqui S. Vincent Rajkumar Robert A. Kyle Shaji K. Kumar Angela Dispenzieri 《American journal of hematology》2020,95(11):1280-1287
Response assessment in light chain (AL) amyloidosis is based on serum and urine monoclonal protein studies. Newly diagnosed patients (n = 373) who achieved very good partial response or complete response (CR) to first line therapy were assessed for the survival impact of each of the monoclonal protein studies. At end of therapy (EOT), negative serum/urine immunofixation (IFE) was achieved in 61% of patients, 72% achieved normal serum free light chain ratio (sFLCR), and the median involved free light chain (iFLC) and difference between involved to uninvolved light chain (dFLC) were 17 mg/L and 5 mg/L, respectively. Overall, 46% of patients achieved a CR at EOT. At EOT, iFLC ≤20 mg/L and dFLC ≤10 mg/L were additive in survival discrimination to negative serum/urine IFE and were independent predictors of overall survival. In contrast, normalization of sFLCR did not add survival discrimination to serum/urine IFE and was not independent predictor of survival. We propose a new definition for hematological CR to include serum/urine IFE negativity plus iFLC ≤20 mg/L or dFLC ≤10 mg/L, instead of the current definition of serum/urine IFE negativity and normal sFLCR. Complete response using dFLC ≤10 mg/L had the best performance in those with significant renal dysfunction and by light chain isotype, making it the preferred partner to IFE. Validation of these results in a multicenter cohort is warranted. 相似文献